Pacific Biosciences Of California (PACB) Operating Expenses (2010 - 2026)

Pacific Biosciences Of California's Operating Expenses history runs 17 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 95.04% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $193.3 million (down 77.17% YoY), while the FY2025 annual figure was $599.6 million, up 17.21% from the prior year.
• Operating Expenses was $21.2 million for Q1 2026 at Pacific Biosciences Of California, down from $57.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $427.6 million in Q1 2025 to a low of $21.2 million in Q1 2026.
• Historically, Operating Expenses has averaged $110.3 million across 5 years, with a median of $91.7 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses jumped 634.72% in 2022, then slumped 95.04% in 2026.
• A 5-year view of Operating Expenses shows it stood at $92.2 million in 2022, then advanced by 5.31% to $97.1 million in 2023, then jumped by 67.92% to $163.1 million in 2024, then tumbled by 64.58% to $57.8 million in 2025, then sank by 63.3% to $21.2 million in 2026.
• The last three Operating Expenses figures came in at $21.2 million (Q1 2026), $57.8 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.